Research programme: epilepsy therapeutics - Biovista

Drug Profile

Research programme: epilepsy therapeutics - Biovista

Alternative Names: BVA-601

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Biovista
  • Class
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • No development reported Epilepsy

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Epilepsy in USA (Parenteral)
  • 03 Apr 2013 Research progamme: epilepsy therapeutics - Biovista is available for licensing as of 03 Apr 2013.
  • 01 Apr 2013 Preclinical trials in Epilepsy in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top